Inactivation of TNF Signaling by Rationally Designed Dominant-Negative TNF VariantsPaul M. Steed, Bassil I. Dahiyat, Alice Kim et al.|Science|2003Cited by 259
Dominant-Negative Inhibitors of Soluble TNF Attenuate Experimental Arthritis without Suppressing Innate Immunity to InfectionJonathan Zalevsky, David E. Szymkowski, Thomas Sécher et al.|The Journal of Immunology|2007Cited by 161
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapyDeborah H. Charych, Jonathan Zalevsky, Samira Khalili et al.|PLoS ONE|2017Cited by 145
NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseasesNeha Dixit, Jonathan Zalevsky, Christie Fanton et al.|Journal of Translational Autoimmunity|2021Cited by 54
NKTR-181: A Novel Mu-Opioid Analgesic with Inherently Low Abuse PotentialTakahiro Miyazaki, Stephen K. Doberstein, Irene Choi et al.|Journal of Pharmacology and Experimental Therapeutics|2017Cited by 46